Prescribing according to body volume instead of body surface New
2-5-2012 - The dosage of many drugs, particularly anti-cancer drugs, is established according to the body area of the patients. In my opinion, this type of prescription is not justified and should be abandoned. suite... | Comments about biopsies and cancers New
2-5-2012 - Two recent letters published in the BMJ point out the potential danger of biopsies so frequently practiced for suspected cancers. suite... |
Vorapaxar, platelet aggregation inhibitor, inhibiting PAR-1 receptor (Protease-Activated Receptor) New
2-5-2012 - Vorapaxar is an antagonist of thrombin on platelets, it blocks the receptor called protease-activated receptor, PAR-1 and thus inhibits the platelet-aggregating effect of thrombin. suite... | Lasmiditan for the treatment of migraine attack New
2-5-2012 - Lasmiditan is an agonist of the serotonin 5-HT1F receptors, it is under investigation for the treatment of migraine attack. suite... |
Treatment of overactive bladder syndrome New
2-5-2012 - The drugs generally used for the treatment of hypereractive bladder are anticholinergics: oxybutinin, trospium, solifenacin, tolterodine. suite... | Antibody to PCSK9 and LDL-cholesterol New
2-5-2012 - The antibody to PSCK9 called REGN727, administered by intravenous or subcutaneous route to people with hypercholesterolemia already treated by atorvastatin, considerably reduced their LDL cholesterol level. suite... |
Insulin alone for type 2 diabetes? New
2-5-2012 - The treatment with metformin plus insulin did not reduce, compared to insulin alone, overall mortality nor cardiovascular mortality but it lowered a little more the level of glycated hemoglobin and induced a lesser weight gain. suite... | Brodalumab and ixekizumab, to treat psoriasis New
2-5-2012 - Two antibodies neutralize the effects of interleukin-17, one blocking the receptor of interleukin-17, brodalumab, and the other neutralizing the interleukin-17 itself, ixekizumab.They are used as investigational drugs for psoriasis. suite... |
Aspirin and cancer
21-4-2012 - The popular press has largely commented on the results of some recent studies showing the benefit of aspirin in preventing and even treating cancer. suite... | Amantadine for severe traumatic brain injury
21-4-2012 - Amantadine at doses ranging between 200 and 400 mg daily, compared to a placebo, accelerated the regression of the disorders of consciousness after traumatic brain injury. suite... |
Ingenol mebutate for actinic keratosis
21-4-2012 - Ingenol mebutate gel applied on actinic keratosis once daily during two or three days,induces a considerable reduction of the importance of the lesions within one or two months. suite... | Peginesatide, Omontys*, for treatment of anemia in adult dialysis patients
21-4-2012 - Peginesatide,is a stimulant of erythropoiesis as erythropoietin but it is different by its structure, it consists of two peptide chains bound chemically and pegylated. It is not genetically obtained. suite... |
Donepezil 23 mg, or how to avoid the competition of the corresponding generics.
21-4-2012 - Eisai Laboratory obtained from the FDA, 4 months before the end of the patent of Aricept*, in fact four months before the possibility of making generics, the authorization to market a presentation of 23 mg(which cannot be obtained by combining 5 and 10 mg). suite... | Dutasteride and progression of the localized prostate cancer
21-4-2012 - In patients with a localized prostate cancer, dutasteride slowed the progression of the disease but preceding results were more ambiguous. suite... |
Surfactant in the respiratory distress syndrome of the newborn
21-4-2012 - Surfactant products have a common name which ends generally in "– actant" such as lucinactant newly marketed in the U.S. under the name Surfaxin*, and others, poractant alpha, beractant, bovactant, calfactant... suite... | Supplementation in vitamin D and calcium in the elderly
21-4-2012 - Supplementation with vitamin D3, or with calcium, or both, compared to placebo, has not changed all-cause mortality, neither cardiovascular mortality, neither cancer mortality, nor cancer incidence. suite... |
 |
|
